| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 140 | 172 | 191 | 222 | 286 | 323 | 396 | 538 | 470 | 581 | 706 | 691 |
| Expenses | 121 | 150 | 166 | 191 | 213 | 213 | 218 | 316 | 332 | 397 | 436 | 431 |
| EBITDA | 20 | 22 | 25 | 31 | 73 | 110 | 178 | 222 | 138 | 184 | 271 | 260 |
| Operating Profit % | 12 % | 12 % | 9 % | 10 % | 23 % | 32 % | 44 % | 40 % | 28 % | 30 % | 37 % | 37 % |
| Depreciation | 3 | 4 | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 22 |
| Interest | 7 | 10 | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 2 | 2 | 2 |
| Profit Before Tax | 10 | 8 | 8 | 15 | 57 | 96 | 167 | 207 | 124 | 166 | 249 | 236 |
| Tax | 2 | 2 | 2 | 6 | 18 | 23 | 44 | 55 | 34 | 47 | 61 | 53 |
| Net Profit | 8 | 6 | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 178 |
| EPS in ₹ | 16.82 | 3.89 | 3.87 | 1.19 | 5.39 | 10.02 | 16.89 | 18.86 | 11.16 | 14.80 | 23.35 | 22.10 |
Supriya Lifescience
Supriya Lifescience
702.00
-39.30
(-5.30%)
There are new updates from the company1 day ago
View
Market Cap
5,649.90 Cr
EPS
23.35
PE Ratio
31.67
Dividend Yield
0.14 %
Industry
Healthcare52 Week High
842.00
52 Week Low
511.40
PB Ratio
5.66
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
Company News
View All News
Supriya Lifescience aims to achieve EBITDA margins of 33-35% in FY26 with 20% year-on-year revenue growth, targeting Rs 1,000 crore by FY27. Executive Chairman Satish Waman Wagh outlined a strategy involving launching 3-4 new products annually, expanding into the US market, and challenging Chinese competitors. The company launched a new anaesthetic product targeting a $300 million market and is in discussions with multinational corporations for a product with $7 billion market potential. Capital expenditure is planned at Rs 65-70 crore for the current year, with Rs 200 crore allocated over three years for the new Patalganga site in Maharashtra. The company focuses on regulated markets with USFDA-compliant manufacturing and backwards integration to maintain cost efficiencies against Chinese competition.
Supriya Lifescience Makes Q1 Earnings Call Transcript Available OnlineAug 19, 2025
Supriya Lifescience Limited has published the transcript of its earnings call held on August 14, 2025, discussing unaudited financial results for the quarter ended June 30, 2025. The transcript is accessible on the company's website. The pharmaceutical company is listed on both NSE (Symbol: SUPRIYA) and BSE (Scrip Code: 543434), operates from Mumbai with manufacturing facilities in Maharashtra, and holds government-recognized export house status.
Supriya Lifescience Plans Growth Through API Exports and Capacity ExpansionAug 13, 2025
Supriya Lifescience is positioning itself to capitalize on API export demand through capacity expansion and backward integration strategies. The company is leveraging regulatory approvals and entering the CRAMS (Contract Research and Manufacturing Services) segment to diversify its revenue streams.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
21.57 %
Net Income Growth
57.85 %
Cash Flow Change
45.34 %
ROE
29.09 %
ROCE
22.19 %
EBITDA Margin (Avg.)
21.23 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 176 | 231 | 241 | 245 | 253 | 336 | 446 | 735 | 820 | 921 | 1,112 |
| Fixed Assets | 61 | 76 | 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 |
| Current Assets | 103 | 129 | 115 | 120 | 133 | 196 | 266 | 498 | 465 | 398 | 437 |
| Capital Work in Progress | 11 | 25 | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 |
| Other Assets | 104 | 131 | 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 448 |
| Total Liabilities | 176 | 231 | 241 | 245 | 253 | 336 | 446 | 735 | 820 | 921 | 1,112 |
| Current Liabilities | 115 | 150 | 144 | 146 | 135 | 155 | 146 | 100 | 96 | 77 | 82 |
| Non Current Liabilities | 23 | 39 | 51 | 45 | 24 | 32 | 31 | 19 | 25 | 29 | 33 |
| Total Equity | 37 | 42 | 46 | 55 | 94 | 149 | 269 | 616 | 700 | 815 | 997 |
| Reserve & Surplus | 33 | 26 | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 |
| Share Capital | 5 | 15 | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1 | 2 | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 |
| Investing Activities | -23 | -33 | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 |
| Operating Activities | -6 | 14 | 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 |
| Financing Activities | 30 | 21 | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 |
Share Holding
| % Holding | May 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 99.98 % | 68.24 % | 68.24 % | 68.24 % | 68.24 % | 68.24 % | 68.28 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % | 68.30 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.34 % | 0.00 % | 5.36 % | 4.95 % | 6.03 % | 6.52 % | 7.19 % | 6.78 % |
| DIIs | 0.00 % | 5.20 % | 4.72 % | 7.27 % | 6.23 % | 7.89 % | 7.65 % | 7.55 % | 7.17 % | 3.85 % | 5.30 % | 5.48 % | 5.45 % | 4.92 % | 4.26 % | 4.86 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 8.25 % | 12.73 % | 12.52 % | 13.40 % | 15.07 % | 15.54 % | 15.39 % | 16.10 % | 17.50 % | 17.06 % | 17.19 % | 0.00 % | 16.28 % | 16.40 % | 16.39 % |
| Others | 0.02 % | 18.30 % | 14.31 % | 11.97 % | 12.13 % | 8.80 % | 8.53 % | 8.76 % | 3.09 % | 10.35 % | 3.98 % | 4.08 % | 20.23 % | 3.98 % | 3.85 % | 3.67 % |
| No of Share Holders | 7 | 50,506 | 82,578 | 86,853 | 94,594 | 96,998 | 95,605 | 93,478 | 92,991 | 95,929 | 87,980 | 89,621 | 85,328 | 89,394 | 91,051 | 91,928 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 0.6 | 0.6 | 0.8 | 1 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.32 | 0.18 | 0.11 | 0.14 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Sept 2022 |  Dividend | ₹ 0.60 /share | 01 Sept 2022 | 355.25 | 355.05 |
| 15 Sept 2023 | Dividend | ₹ 0.60 /share | 15 Sept 2023 | 257.55 | 292.40 |
| 21 Sept 2024 | Dividend | ₹ 0.80 /share | 20 Sept 2024 | 360.75 | 630.75 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 627.75 | 588.85 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 555.10 | 547.30 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 669.40 | 730.35 |
| 27 May 2025 | Quarterly Result Announcement | NA | 27 May 2025 | 701.60 | 742.45 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 658.25 | 651.90 |
| 05 Sept 2025 | Dividend | ₹ 1.00 /share | 04 Sept 2025 | 742.45 | 655.60 |
| 24 Sept 2025 | Annual General Meeting | NA | 24 Sept 2025 | 662.85 | 738.20 |
Announcements
Closure of Trading Window
1 day ago
1 day agoVoting Results For 17Th Annual General Meeting3 days ago
3 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report3 days ago
3 days agoShareholder Meeting / Postal Ballot-Outcome of AGM3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Sep 02, 2025Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company Providing WeblinkSep 02, 2025
Sep 02, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 01, 2025
Sep 01, 2025Reg. 34 (1) Annual Report.Sep 01, 2025
Sep 01, 2025Notice Of 17Th Annual General Meeting Of Members Of The Company Scheduled To Be Held On Wednesday September 24 2025.Sep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Sep 01, 2025Intimation Of Record Date For 17Th AGM Of The Company Scheduled On September 24 2025.Aug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Aug 13, 2025Amendment In Policy/Code Of The CompanyAug 13, 2025
Aug 13, 2025Unaudited Financial Result For The Quarter Ended On June 30 2025Aug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13 2025Aug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30 2025Aug 06, 2025
Aug 06, 2025Clarification Regarding Shareholder Demat RequestsJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Email Communication To Shareholders Regarding Dividend Taxation ProvisionsJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 31, 2025
May 31, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 27, 2025
May 27, 2025Appointment Of Secretarial Auditor For Term Of Five (5) Consecutive YearsMay 27, 2025
May 27, 2025Corporate Action-Board to consider DividendMay 27, 2025
May 27, 2025Audited Financial Result For Quarter And Year Ended On March 31 2025May 27, 2025
May 27, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On May 27 2025May 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 21, 2025
May 21, 2025Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended March 31 2025 And Recommend Dividend If Any On The Equity Shares Of The Company For The Financial Year Ended March 31 2025May 20, 2025
May 20, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 28, 2025
Apr 28, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 24, 2025
Apr 24, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 01, 2025
Apr 01, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 25, 2025
Mar 25, 2025Technical Indicators
RSI(14)
Neutral 54.91
ATR(14)
Volatile 22.38
STOCH(9,6)
Overbought 83.26
STOCH RSI(14)
Neutral 74.01
MACD(12,26)
Bullish 7.45
ADX(14)
Strong Trend 26.16
UO(9)
Bearish 52.75
ROC(12)
Uptrend And Accelerating 7.25
WillR(14)
Neutral -46.40
Mutual Fund Holdings
Samco Multi Cap Fund Direct-Growth 
Quantum Small Cap Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Bandhan Nifty Total Market Index Fund Direct-Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
